Novo Nordisk Stock Falls Amid Pipeline Concerns
Shares of Novo Nordisk (NVO) dropped more than 4% on Monday following a disappointing capital markets day where the company did not provide enough detail about near-term growth targets. The weight-loss drug maker outlined ambitions for over $23 billion in pipeline sales by 2035 and plans to launch multiple blockbuster drugs, but investors remained skeptical amid growing competition. Novo Nordisk CEO Mike Doustdar acknowledged that the market has become highly competitive since the company helped create it with its GLP-1 therapies. He emphasized the need for readiness as nearly every pharmaceutical firm is now vying in this space. Doustdar also highlighted his focus on improving Wegovy marketing and investing more aggressively in R&D to address future patent expirations. The CEO, who took over in August 2025 after a long career at Novo Nordisk, stressed the importance of maintaining market leadership post-patent cliff. He mentioned exploring partnerships and acquisitions as part of his strategy for continued growth.
Topics: CEO strategy GLP-1 drugs pharmaceuticals R&D investment Wegovy